PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple…
Articles by Magdalena Kegel
Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with  Velcade…
Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic…
The U.S. Food and Drug Administration (FDA) has ordered Merck to suspend two Phase…
The U.S. Food and Drug Administration (FDA) recently approved a lab test to aid in the detection and diagnosis of…
Oncology Venture has enrolled the first patient into a Phase 1/2 trial of its compound APO010 in multiple myeloma.
GlycoMimetics’ GMI-1271 restored the punch of the myeloma treatment Velcade (bortezomib) in mice, which should rekindle hope in patients…
Janssen Biotech will discuss at a Chicago cancer conference the effectiveness of new multiple myeloma treatment combinations that include…
Treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD), in addition to a stem cell transplant, improved progression-free…
A rabbit virus slowed the growth of multiple myeloma in mice, and eradicated the cancer in a fourth of the…